CTKB (Cytek Biosciences) Momentum Rank: 8 (As of Aug. 07, 2026) — 60% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTKB Cytek Biosciences Inc CTKB
71 GF Score
Price $4.16
GF Value $5.52
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cytek Biosciences Momentum Rank?

Cytek Biosciences CTKB -0.48% 71 Momentum Rank is 8 as of Aug. 07, 2026, which is 60% above its 10-year median of 5.00. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.52 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Cytek Biosciences has the Momentum Rank of 8.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Cytek Biosciences Momentum Rank Related Terms

CTKB vs CERS, TCMD, CBLL: Momentum Rank Comparison

For the Medical Devices subindustry, Cytek Biosciences's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytek Biosciences Momentum Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Cytek Biosciences's Momentum Rank falls into.


CTKB
71GF Score
Cytek Biosciences Inc CTKB
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 8 mean?
Cytek Biosciences (CTKB) has a Momentum Rank of 8 as of Aug. 07, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Cytek Biosciences and its competitors. This is 60% above median its historical median of 5.00. Over the past decade, Cytek Biosciences' Momentum Rank has ranged from 2.00 to 8.00.
Is Cytek Biosciences' Momentum Rank too high?
Cytek Biosciences' current Momentum Rank of 8 is 60% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Momentum Rank compare to CERS and TCMD?
Cytek Biosciences' Momentum Rank of 8 can be compared against companies in the Medical Devices & Instruments industry. Historically, Cytek Biosciences' own Momentum Rank has ranged from 2.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Medical Devices & Instruments company?
A good Momentum Rank depends on the Medical Devices & Instruments industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Cytek Biosciences and its competitors. Cytek Biosciences's current Momentum Rank is 8, which is 60% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.52, compared to a current price of $4.16 — trading 24.6% below its estimated fair value. The current Momentum Rank is 8, which is 60% above median its 10-year median of 5.00. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Momentum Rank is 8 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytek Biosciences (CTKB) Overvalued in 2026?

Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued. The current stock price of $4.16 is trading 24.6% below its estimated GF Value™ of $5.52. GuruFocus considers Cytek Biosciences to be Modestly Undervalued.

Key valuation signals for CTKB:

  • Momentum Rank: 8 (60% above median its 10-year median of 5.00)
  • GF Value™: $5.52 vs. price of $4.16 (24.6% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytek Biosciences Business Description

Other Exchanges 8EQ:Germany
Address 47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score

Get the complete analysis for CTKB

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.16
Price
$5.52
GF Value